Compare Inovio Pharmaceuticals Inc (INO) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Rockwell Automation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.78 (market cap $78.67M), while Rockwell Automation trades at $452.77 (market cap $50.13B). The key difference: Rockwell Automation is far larger — about 637.2× Inovio Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.22% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | ROK | |
|---|---|---|
Market Cap | $78.67M | $50.13B |
Sector | Health | Industrials |
52-Week High | $2.87 | $495.08 |
52-Week Low | $0.66 | $333.75 |
Enterprise Value | $50.00M | $53.26B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Rockwell Automation (ROK) trades at $451.86, up 3.82% over 24 hours, with a neutral technical signal. The stock exhibits strong fundamentals, including a 49.09% gross margin and consistent earnings beats, with Q2 2026 EPS of $3.49 surpassing the $3.38 estimate. Recent news highlights AI integration in quality management systems, signaling innovation momentum. Valuation ratios are elevated, with a P/E of 41.85 and P/S of 5.6, reflecting premium pricing.
The outlook remains positive due to robust earnings performance and raised fiscal 2026 guidance, though high valuation multiples and inflation pressures pose risks. Analyst consensus is a Buy with a $507 price target, suggesting 12% upside. Key risks include cost inflation and competitive threats in industrial automation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
